Literature DB >> 27524416

mTOR promotes pituitary tumor development through activation of PTTG1.

R Chen1, J Duan1, L Li1, Q Ma1, Q Sun1, J Ma1, C Li1, X Zhou1, H Chen1, Y Jing1, S Zhao1, X Wu2, H Zhang1.   

Abstract

As one of the most common intracranial tumors, pituitary tumor is associated with high morbidity. Effective therapy is currently not available for some pituitary tumors due to the largely undefined pathological processes of pituitary tumorigenesis. In this study, hyperactivation of mammalian/mechanistic target of rapamycin (mTOR) signaling was observed in estrogen-induced rat pituitary tumor and mTOR inhibitor rapamycin blocked the tumor development. Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment. Mechanistically, the expression of pituitary tumor transforming gene 1 (PTTG1) was upregulated in an mTOR complex 1-dependent manner. Overexpressed PTTG1 was crucial in hyperactive mTOR-mediated tumorigenesis. mTOR-PTTG1 signaling axis may be targeted for the treatment of tumors with mTOR hyperactivation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27524416     DOI: 10.1038/onc.2016.264

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

1.  Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene.

Authors:  Ralf Lesche; Matthias Groszer; Jing Gao; Ying Wang; Albee Messing; Hong Sun; Xin Liu; Hong Wu
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

2.  Pituitary tumor transforming gene overexpression facilitates pituitary tumor development.

Authors:  Ines Donangelo; Shiri Gutman; Eva Horvath; Kalman Kovacs; Kolja Wawrowsky; Michael Mount; Shlomo Melmed
Journal:  Endocrinology       Date:  2006-06-29       Impact factor: 4.736

3.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

4.  Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.

Authors:  Amy J Malhowski; Haider Hira; Sarah Bashiruddin; Rod Warburton; June Goto; Blanton Robert; David J Kwiatkowski; Geraldine A Finlay
Journal:  Hum Mol Genet       Date:  2011-01-06       Impact factor: 6.150

5.  Enhanced protein kinase B/Akt signalling in pituitary tumours.

Authors:  M Musat; M Korbonits; B Kola; N Borboli; M R Hanson; A M Nanzer; J Grigson; S Jordan; D G Morris; M Gueorguiev; M Coculescu; S Basu; A B Grossman
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

6.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

7.  Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Authors:  Laifong Lee; Paul Sudentas; Brian Donohue; Kirsten Asrican; Aelaf Worku; Victoria Walker; Yanping Sun; Karl Schmidt; Mitchell S Albert; Nisreen El-Hashemite; Alan S Lader; Hiroaki Onda; Hongbing Zhang; David J Kwiatkowski; Sandra L Dabora
Journal:  Genes Chromosomes Cancer       Date:  2005-03       Impact factor: 5.006

8.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

9.  Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin.

Authors:  Cristiane H Squarize; Rogerio M Castilho; J Silvio Gutkind
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

Review 10.  Genetically engineered mouse models of pituitary tumors.

Authors:  David A Cano; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Front Oncol       Date:  2014-08-01       Impact factor: 6.244

View more
  16 in total

1.  Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary.

Authors:  Nandar Tun; Yasuaki Shibata; Myat Thu Soe; Myo Win Htun; Takehiko Koji
Journal:  Histochem Cell Biol       Date:  2018-12-03       Impact factor: 4.304

2.  mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.

Authors:  Chunjia Li; Hongyu Chen; Zhou Lan; Shaozong He; Rongrong Chen; Fang Wang; Zhibo Liu; Kai Li; Lili Cheng; Ye Liu; Kun Sun; Xiaofeng Wan; Xinxin Chen; Haiyong Peng; Li Li; Yanjun Zhang; Yanling Jing; Min Huang; Yanan Wang; Yan Wang; Jiandong Jiang; Xiaojun Zha; Ligong Chen; Hongbing Zhang
Journal:  Cell Death Differ       Date:  2019-02-13       Impact factor: 15.828

3.  Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.

Authors:  Claudia Pivonello; Roberta Patalano; Domenico Solari; Renata S Auriemma; Federico Frio; Francesca Vitulli; Ludovica F S Grasso; Marialuisa Di Cera; Maria Cristina De Martino; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2018-07-31       Impact factor: 3.633

Review 4.  Aggressive prolactinoma (Review).

Authors:  Ana Valea; Florica Sandru; Aida Petca; Mihai Cristian Dumitrascu; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

5.  TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis.

Authors:  Ling Hao; Boyu Du; Xueyan Xi
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 6.  Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance.

Authors:  Yang-Hsiang Lin; Kwang-Huei Lin; Chau-Ting Yeh
Journal:  Front Med (Lausanne)       Date:  2020-05-22

7.  Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours.

Authors:  Ze Rui Wu; Lichong Yan; Yan Ting Liu; Lei Cao; Yu Hang Guo; Yong Zhang; Hong Yao; Lin Cai; Han Bing Shang; Wei Wei Rui; Gang Yang; Xiao Biao Zhang; Hao Tang; Yu Wang; Jin Yan Huang; Yong Xu Wei; Wei Guo Zhao; Bing Su; Zhe Bao Wu
Journal:  Nat Commun       Date:  2018-11-05       Impact factor: 14.919

Review 8.  The Treatment of Refractory Pituitary Adenomas.

Authors:  Congxin Dai; Xiaohai Liu; Wenbin Ma; Renzhi Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-29       Impact factor: 5.555

9.  Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.

Authors:  Weijie Zhou; Dalang Fang; Yongfei He; Jie Wei
Journal:  J Gastrointest Oncol       Date:  2021-06

10.  Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas.

Authors:  Zerui Wu; Yunqiu Xu; Jiadong Xu; Jianglong Lu; Lin Cai; Qun Li; Chengde Wang; Zhipeng Su
Journal:  Oxid Med Cell Longev       Date:  2021-06-16       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.